Literature DB >> 30510250

Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers.

Wouter Scheper1, Sander Kelderman2, Lorenzo F Fanchi1, Carsten Linnemann2, Gavin Bendle2, Marije A J de Rooij2, Christian Hirt3, Riccardo Mezzadra1, Maarten Slagter1,4, Krijn Dijkstra2, Roelof J C Kluin5, Petur Snaebjornsson6, Katy Milne7, Brad H Nelson7, Henry Zijlmans8, Gemma Kenter8, Emile E Voest2,9, John B A G Haanen2,9, Ton N Schumacher10.   

Abstract

Infiltration of human cancers by T cells is generally interpreted as a sign of immune recognition, and there is a growing effort to reactivate dysfunctional T cells at such tumor sites1. However, these efforts only have value if the intratumoral T cell receptor (TCR) repertoire of such cells is intrinsically tumor reactive, and this has not been established in an unbiased manner for most human cancers. To address this issue, we analyzed the intrinsic tumor reactivity of the intratumoral TCR repertoire of CD8+ T cells in ovarian and colorectal cancer-two tumor types for which T cell infiltrates form a positive prognostic marker2,3. Data obtained demonstrate that a capacity to recognize autologous tumor is limited to approximately 10% of intratumoral CD8+ T cells. Furthermore, in two of four patient samples tested, no tumor-reactive TCRs were identified, despite infiltration of their tumors by T cells. These data indicate that the intrinsic capacity of intratumoral T cells to recognize adjacent tumor tissue can be rare and variable, and suggest that clinical efforts to reactivate intratumoral T cells will benefit from approaches that simultaneously increase the quality of the intratumoral TCR repertoire.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30510250     DOI: 10.1038/s41591-018-0266-5

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  169 in total

Review 1.  T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies.

Authors:  Melinda A Biernacki; Michelle Brault; Marie Bleakley
Journal:  Cancer J       Date:  2019 May/Jun       Impact factor: 3.360

2.  SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.

Authors:  Siwen Hu-Lieskovan; Srabani Bhaumik; Kavita Dhodapkar; Jean-Charles J B Grivel; Sumati Gupta; Brent A Hanks; Sylvia Janetzki; Thomas O Kleen; Yoshinobu Koguchi; Amanda W Lund; Cristina Maccalli; Yolanda D Mahnke; Ruslan D Novosiadly; Senthamil R Selvan; Tasha Sims; Yingdong Zhao; Holden T Maecker
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

Review 3.  Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.

Authors:  Livius Penter; Catherine J Wu
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 4.  Microbiota-Propelled T Helper 17 Cells in Inflammatory Diseases and Cancer.

Authors:  Matteo Bellone; Arianna Brevi; Samuel Huber
Journal:  Microbiol Mol Biol Rev       Date:  2020-03-04       Impact factor: 11.056

Review 5.  Applications of molecular engineering in T-cell-based immunotherapies.

Authors:  David A McBride; Matthew D Kerr; Shinya L Wai; Nisarg J Shah
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-04-10

Review 6.  CD8+ T cell states in human cancer: insights from single-cell analysis.

Authors:  Anne M van der Leun; Daniela S Thommen; Ton N Schumacher
Journal:  Nat Rev Cancer       Date:  2020-02-05       Impact factor: 60.716

Review 7.  Antitumour dendritic cell vaccination in a priming and boosting approach.

Authors:  Alexandre Harari; Michele Graciotti; Michal Bassani-Sternberg; Lana E Kandalaft
Journal:  Nat Rev Drug Discov       Date:  2020-08-06       Impact factor: 84.694

Review 8.  Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections.

Authors:  Mary Philip; Andrea Schietinger
Journal:  Curr Opin Immunol       Date:  2019-06-08       Impact factor: 7.486

9.  Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non-Small Cell Lung Cancer.

Authors:  Shaun M O'Brien; Astero Klampatsa; Jeffrey C Thompson; Marina C Martinez; Wei-Ting Hwang; Abishek S Rao; Jason E Standalick; Soyeon Kim; Edward Cantu; Leslie A Litzky; Sunil Singhal; Evgeniy B Eruslanov; Edmund K Moon; Steven M Albelda
Journal:  Cancer Immunol Res       Date:  2019-05-03       Impact factor: 11.151

10.  T-cell Receptors Engineered De Novo for Peptide Specificity Can Mediate Optimal T-cell Activity without Self Cross-Reactivity.

Authors:  Preeti Sharma; Daniel T Harris; Jennifer D Stone; David M Kranz
Journal:  Cancer Immunol Res       Date:  2019-09-23       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.